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Patient-specific induced pluripotent stem cells
(iPSCs) derived from somatic cells provide a unique
tool for the studyof humandisease, aswell as aprom-
ising source for cell replacement therapies. One
crucial limitation has been the inability to perform
experiments under genetically defined conditions.
This is particularly relevant for late age onset disor-
ders in which in vitro phenotypes are predicted to
be subtle and susceptible to significant effects of
genetic background variations. By combining zinc
finger nuclease (ZFN)-mediated genome editing
and iPSC technology, we provide a generally appli-
cable solution to this problem, generating sets of
isogenic disease and control human pluripotent
stem cells that differ exclusively at either of two
susceptibility variants for Parkinson’s disease by
modifying the underlying point mutations in the
a-synuclein gene. The robust capability to genetically
correct disease-causing point mutations in patient-
derived hiPSCs represents significant progress for
basic biomedical research and an advance toward
hiPSC-based cell replacement therapies.
INTRODUCTION
Extraordinary excitement over progress in the ability of genomic
medicine to connect specific genotypes to disease predisposi-
tion has been tempered by the host of challenges in translating
such correlations to specific treatments. There is consensus in
the field that modeling ‘‘diseases in a dish’’ is one of the most
promising approaches to address this crucial problem (Vogel,318 Cell 146, 318–331, July 22, 2011 ª2011 Elsevier Inc.2010). Human induced pluripotent stem cell (hiPSC) technology,
which enables the epigenetic reprogramming of human somatic
cells into an embryonic stem cell-like state followed by differen-
tiation into any cell type of the body, is being developed as a key
component of such in vitro disease modeling (Dimos et al., 2008;
Park et al., 2008; Soldner et al., 2009; Takahashi et al., 2007; Yu
et al., 2007). In principle, patient-specific iPSCs that carry all
disease-relevant genetic alterations could provide researchers
with a unique opportunity to study the cellular and molecular
mechanisms of monogenic and complex diseases in relevant
cell types in vitro with the potential to identify alternative treat-
ments (Daley and Scadden, 2008; Saha and Jaenisch, 2009).
However, so far, only a few such studies have identified
disease-related phenotypes, mostly in rare, early age onset or
metabolic diseases (Brennand et al., 2011; Ebert et al., 2009; Itz-
haki et al., 2011; Lee et al., 2009; Marchetto et al., 2010; Rashid
et al., 2010). Due to the robust and rapid manifestation of these
disorders, in vitro models are more likely to display clear differ-
ences when compared to healthy donor controls. In contrast,
late age onset disorders, such as Parkinson’s and Alzheimer’s
diseases, with long latency and slow progression of cellular
and pathological changes in vivo are expected to show only
subtle phenotypes in vitro. To distinguish these subtle but
disease-relevant phenotypical changes from unpredictable
background-related variations could prove difficult due to the
lack of genetically matched controls. Commonly used control
cells from healthy donors represent an approximate solution at
best because individual hESC and hiPSC lines display highly
variable biological characteristics such as the propensity to
differentiate into specific functional cells (Bock et al., 2011;
Boulting et al., 2011; Soldner et al., 2009). The basis for these
profound differences is manifold and includes: (1) differences
in genetic background; (2) the process of cell derivation (Lengner
et al., 2010); and (3) in the case of hiPSCs, variegation effects and
residual transgene expression of the viral vectors used to induce
reprogramming (Soldner et al., 2009) and genetic alterations
introduced during the reprogramming process (Gore et al.,
2011; Hussein et al., 2011). Variable genetic background pres-
ents a particularly significant impediment to in vitro disease
modeling approaches because it is not possible to control for
effects from genetic modifier loci. Even mutations that cause
the most prevalent monogenic diseases, including sickle cell
anemia, cystic fibrosis, and dominant forms of familial Parkin-
son’s disease (PD), are susceptible to significant epistatic effects
of genetic background that result in incomplete penetrance and
variable age of onset and disease progression (Lees et al., 2009;
Summers, 1996).
Therefore, for the disease in a dish approach to be successful,
it is essential to set up experimental systems in which the
disease-causing genetic lesion of interest is the sole modified
variable. However, the unresolved problem of genetically manip-
ulating pluripotent human cells has prevented the creation of
such genetically defined human model systems. Recently, we
and others used engineered zinc finger nucleases (ZFNs) to drive
efficient targeted integration of selectable markers into hESCs
and hiPSCs (Hockemeyer et al., 2009; Zou et al., 2009). Employ-
ing this technology (referred to as ‘‘genome editing’’), we present
here a generally applicable solution to this key problem by
demonstrating the generation of a panel of isogenic disease
and control cell lines from hESCs and hiPSCs that differ exclu-
sively at well-validated susceptibility variants for PD by geneti-
cally modifying single base pairs in the a-synuclein gene.
PD, the second most common late age onset neurodegener-
ative disorder, is characterized primarily by major loss of nigros-
triatal dopaminergic neurons and the presence of proteinacious
inclusion bodies (Lewy bodies) in affected cells. The discovery
of mutations linked to rare forms of familial PD, such as domi-
nant mutations in a-synuclein (A53T, E46K, A30P), the major
component of Lewy bodies, has provided vital clues in under-
standing the molecular pathogenesis not only of the rare
familial, but also of the more prevalent sporadic forms of the
disease (Lees et al., 2009; Schulz, 2008). However, cellular
and transgenic animal models expressing such mutants only
partially recapitulate PD pathology (Dawson et al., 2010). In
order to develop a genetically defined human in vitro model of
PD, we sought to generate a panel of control and disease-
related cell lines by either deriving hiPSCs from a patient
carrying the A53T (G209) a-synuclein mutation followed by the
correction of this mutation or, alternatively, by generating either
the A53T (G209A) or E46K (G188A) mutation in the genome of
wild-type hESCs.
RESULTS
Insertion of Disease-Causing A53T (G209A) a-Synuclein
Mutation into hESCs
Genome editing with engineered ZFNs relies on a double-strand
break (DSB) introduced by the nucleases. The ability to precisely
target DSB to an investigator-specified site is critical because
point mutations are transferred with maximal efficiency from
episomal donors into the position of the DSB itself (Elliott et al.,
1998; Goldberg et al., 2010). We engineered a panel of ZFNs
that introduces a DSB precisely at nucleotide base 209 (site ofA53T mutation) in exon 3 of the a-synuclein gene (Figures 1A
and 1B and Table S1 and Table S2 available online). Screening
of the ZFNs in transformed human cells demonstrated editing
of up to 18% of a-synuclein alleles precisely at the intended
site (Figure 1A).
Guided by our previous results on highly efficient targeted
integration of genes in hESCs and hiPSCs (Hockemeyer et al.,
2009), we initially considered a drug selection-based strategy
to introduce the PD-causing A53T (G209A) mutation into the
endogenous a-synuclein locus in hESCs. However, for many
disease-related mutations that are located within protein-coding
exons, including a-synuclein A53T (G209A), the same approach
cannot be used because insertion of the selection marker would
disrupt the expression of the targeted gene. We therefore
devised an alternative strategy based on the insertion of a loxP
site flanked puromycin resistance gene in the adjacent intron
23 bases downstream of the A53T a-synuclein mutation and
the DSB (Figure 1B). For this gene editing strategy, a correct tar-
geting event followed by Cre-recombinase-mediated excision of
the selection cassette is expected to result in a single base pair
change that creates the A53T (G209A) mutation in exon 3 of
a-synuclein, with a remaining single loxP site in the following
intron (Figure 1B).
The targeting donor construct (Syn-A53T-loxP-pGK-puro-
loxP) comprising 600 bp homology on each side of the ZFN-
targeted site carrying the A53T (G209A) mutation (Figure 1B),
together with four distinct ZFN pairs (Table 1, Figure 1A, Table
S1, and Table S2), were electroporated into two different hESC
lines (BGO1 and WIBR3). Southern blot analysis of individual
single-cell-derived puromycin-resistant clones using probes 50
and 30 external to the donor homology region demonstrated
the disruption of the genomic locus and integration of the target-
ing donor vector with a frequency of at least 25% (Figure 1C, Fig-
ure S1A, and Table 1). Further analysis using an internal probe
against the 30 targeting arm of the donor vector (Figure S1B)
and against the ampicillin resistance gene (Figure S1C) revealed
integrations of additional donor-derived vector sequences into
the target locus, presumably via a hybrid homology directed
repair (HDR)-end-joining-based process such as described
previously (Richardson and Jasin, 2000).
Three out of 336 puromycin-resistant clones showed the
correct modification of the targeted genomic locus by Southern
blot (Figure 1C, Figure S1, and Table 1), which was further con-
firmed by sequencing after Cre-mediated excision of the selec-
tion cassette (Figure 1D). Two out of the three clones carried
a small deletion in the second allele as a result of ZFN-mediated
gene disruption. The correctly targeted clone with a nondisrup-
ted wild-type allele (WIBR3-SNCAA53T/WT-1A/-1C) displayed
a normal karyotype (Figure S1D) and maintained a pluripotent
state, as indicated by the uniform expression of pluripotency-
specific marker proteins (Figure 1E) and the ability to form tera-
tomas comprising cell types originating from all three develop-
mental germ layers (Figure 1F). The stable integration of the
transiently transfected ZFN or Cre-recombinase-expressing
plasmids was excluded by Southern blot analysis (Figure S3).
Furthermore, using an embryoid body (EB)-based protocol to
induce neural differentiation, we were able to efficiently derive
dopaminergic thyrosine hydroxylase (TH)-expressing neuronsCell 146, 318–331, July 22, 2011 ª2011 Elsevier Inc. 319
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from the targeted hESC line (Figure 1G). To verify that the loxP
site remaining after Cre-mediated excision of the selection
cassette does not interfere with the splicing or gene expression
of a-synuclein, we differentiated the parental and targeted
hESC lines into neurons in order to induce expression of
a-synuclein. Mutation analysis RT-PCR (Polymeropoulos
et al., 1997) confirmed that the levels and ratio of expression
of the wild-type and the A53T-mutated transcript in the targeted
cell line were similar to those observed in neurons derived
from A53T patient-specific hiPSCs (WIBR-iPS-SNCAA53T(1lox))
(Figure 1H).
In order to increase the targeting efficiency by reducing non-
targeted integrations of the donor vector, as well as integration
of donor vector sequences that are outside of the homology
arms at the site of ZFN cleavage, we employed a positive-nega-
tive selection strategy (Capecchi, 1989) by incorporating the
herpes simplex virus thymidine kinase (HSV-TK) and diphtheria
toxin A-chain (DT-A) into the vector backbone (Figure 1B). Using
this strategy, 9 out of 41 puromycin- and ganciclovir-resistant
colonies resulted in a correctly targeted allele (Figure 1I and
Table 1). Four of these clones had no disruption of the second
wild-type allele, and 1 out of the 41 clones resulted in correct tar-
geting and insertion of the A53T (G209A) mutation into both
alleles (WIBR3-SNCAA53T/A53T). The targeted clones initially
identified by Southern blot analysis were confirmed by
sequencing of the genomic locus (data not shown). None of
the clones integrated the transiently transfected ZFNs (Fig-
ure S3). This single step biallelic modification of a disease-rele-
vant locus represents a unique tool to study the role of mutant
a-synuclein in the absence of the wild-type protein. Individuals
that are homozygous for this mutation have not been described,
and the study of homozygous mutant cells may provide new
insights into the pathogenesis of PD.Figure 1. ZFN-Mediated Insertion of the A53T (G209A) a-Synuclein Mu
(A) Screening of ZFNs directed against nucleotide 209 of exon 3 of human a-synu
Cel-1 assay. Red arrows indicate expected Cel-1 digest products. The frequency
GFP-transfected negative control). All ZFNs were linked to wild-type FokI except p
endonuclease (ELD-KKR).
(B) Schematic overview depicting the genomic a-synuclein locus (SNCA) and the
external and internal Southern blot probes (red bars). Enlarged sequence indicate
insertion site of loxP-site-flanked pGK-puro selection cassette (red box). Shown
(Syn-A53T-loxP-pGK-puro-loxP) or positive-negative selection (Syn-A53T-loxP-
Cre-excision of the selection cassette. Donor plasmids comprise 600 bp hom
promoter; puro, puromycin resistance gene; pGKpolyA, polyadenylation sequen
toxin A-chain.
(C) Southern blot analysis of hESC line WIBR3 targeted with donor plasmid Syn-
SNCAA53T/WT-1C) Cre-mediated excision of the selection cassette. Genomic DNA
probe and internal 30probe. Fragment sizes for each digest are indicated.
(D) Sequencing of genomic a-synuclein locus in hESC line WIBR3-SNCAA53T/WT
base) sequence. Targeted allele contains the remaining loxP site after Cre-media
(E) Immunofluorescence staining of WIBR3-SNCAA53T/WT-1C for the pluripotency
(F) Hematoxylin and eosin staining of teratoma sections generated from WIBR3-
(G) Immunofluorescence staining of neuronal cultures derived from WIBR3-SNC
class III b-tubulin (TUJ1; green) and the dopaminergic neuron-specific marker ty
(H) Mutation analysis RT-PCR of a-synuclein transcript (± Tsp45I restriction dige
site.) Expected fragment size after Tsp45I digest: wild-type transcript, 249/218/24
restriction fragments are indicated by red arrows).
(I) Southern blot analysis of WIBR3 cells targeted with donor plasmid Syn-A53T-l
DNA was digested with indicated enzymes and hybridized with the external 50 an
(WIBR3-SNCAA53T/WT-2 line shows correct targeting of one allele; WIBR3-SNCAInsertion of the A53T (G209A) Point Mutation into the
a-Synuclein Gene without Drug Selection
The experiments described thus far, though successful in trans-
ferring a desired point mutation to the native locus, required the
integration of a selectable marker into a neighboring intron.
Dependent on the location of the desired editing events relative
to intron/exon junction, such strategy may not be applicable to
all genes; in addition, whereas the selectable marker can be
excised using Cre-recombinase, the remaining loxP site repre-
sents an additional nonrequired genetic alteration with possible
unpredictable effects. We therefore turned to an approach
aimed at generating genetically pristine hESCs that contain no
exogenous sequences other than the edited base (Urnov et al.,
2005) for introducing the disease-causing point mutation (Fig-
ure 2A). Given the high gene editing activity of the ZFNs (Fig-
ure 1A, Figure S1A, and Table 1), we constructed a donor vector
lacking a selection cassette, consisting only of 1 kb homology
flanking the ZFN cleavage site carrying the A53T (G209A) point
mutation in order to insert themutation in the endogenous a-syn-
uclein locus in hESCs (Figure 2A). The hESC line BGO1was elec-
troporated with the donor construct together with ZFNs and an
eGFP-expressing plasmid, which allows transfected cells to be
enriched by fluorescence-activated cell sorting (FACS). Single-
cell-derived colonies derived from this enriched pool were
screened by Southern blot analysis using an A53T (G209A)
allele-specific Tsp45I restriction digest. Three out of 240 BGO1
clones showed the A53T (G209A) allele-specific restriction
pattern, indicative of an accurate genetic alteration event result-
ing in a A53T (G209A) mutation at the endogenous genomic
locus (Figure 2B). Further analysis byPCRgenotyping (Figure 2C)
and sequencing of the genomic locus (Figure 2D) confirmed one
correctly targeted clone (Table 1) with the expected single base
pair change of nucleotide 209 on one allele and an unaffectedtation in hESCs Using a Drug Selection-Based Targeting Strategy
clein. ZFN-mediated disruption of target locus was measured by the Surveyor/
of gene disruption of each ZFN pair is indicated below each lane (GFP indicates
air SNCA-L1/R3, which was linked to an obligate heterodimer form of the Fok1
targeting strategy showing exons (blue boxes), restriction sites, and location of
s ZFN-induced cut site at base 209 in exon 3 of a-synuclein (red base pair) and
below is a schematic of the donor plasmid design for either positive selection
pGK-puro-loxP-HSV-TK-DT-A) and targeted genomic locus before and after
ology on each side of the ZFN cut. pGK-promoter, phosphoglycerol kinase
ce; HSV-TK, herpes simplex virus thymide kinase; pGK-DT-A-pA, diphtheria
A53T-loxP-pGK-puro-loxP before (WIBR3-SNCAA53T/WT-1) and after (WIBR3-
was digested with indicated enzymes and hybridized with the external 30 and 50
-1C showing either wild-type (G209, blue base) or targeted mutant (A209, red
ted excision of selection cassette.
markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.
SNCAA53T/WT-1C cells.
AA53T/WT-1C cells 10 days after induction of differentiation for neuron-specific
rosine hydroxylase (TH; red).
st) in indicated cell lines. (A53T mutation creates additional Tsp45I restriction
/9 bp; A53T transcript, 249/185/33/ 24/9 bp (A53T- and wild-type [WT]-derived
oxP-pGK-puro-loxP-HSV-TK-DT-A after positive-negative selection. Genomic
d 30 probe and internal 30probe. Fragment sizes for each digest are indicated
A53T/A53T line shows correct targeting of both alleles).
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Table 1. Summary of ZFN-Mediated Genome Editing Experiments and Analyzed Clones
Cell Line
Donor Vector/
ssODN ZFN Pair
Number of
Clones
Analyzed
Number of
Clones with
Modified
Target Locus
Number of Clones
with Correctly
Targeted Allele
(Second Allele
Disrupted)
Number of
Correctly
Targeted/
Analyzed
Clones
Number of
Off-Target
Modifications/
Tested Sites
Cell Line
Designation
BGO1 Donor-Syn-
A53T-loxP-
pGK-puro-loxP
ZFN L1/R1
ZFN L2/R1
ZFN L1/R2
ZFN L2/R2
60
60
60
60
17a
18a
17a
23a
1 (1)
1 (1)
0/240
WIBR3 Donor-Syn-
A53T- loxP-
pGK-puro-loxP
ZFN L1/R1 96 12a 1 (0) 1/96 0/38 WIBR3-
SNCAA53T/WT
1A,1B,1Cd
WIBR3 Donor-Syn-A53T- loxP-
pGK-puro-loxP-HSV-
TK-DT-A (positive-
negative selection)
ZFN L1/R3 41 one
allele: 17a
both
alleles: 2a
9 (5)
2 (1)
4/41
1/41
0/24f
0/12
WIBR3-
SNCAA53T/WT
2,3,4,5
WIBR3-
SNCAA53T/A53T
WIBR3 ssODN-E46K ZFN L1/R3 480 4g 4 (0) 4/480 nd WIBR3-
SNCAE46K
1,2,3,4
BGO1 Donor-Syn-A53T
(no selection)
ZFN L1/R1 240 3b 2 (1) 1/240 0/38 BGO1-
SNCAA53T/WT
BGO1 ssODN-E46K ZFN L1/R3 240 1g 1 (0) 1/240 nd BGO1-
SNCAE46K
WIBR-iPS-
SNCAA53T-5
Donor-Syn-WT
(no selection)
ZFN L1/R1 240 6c 2 (1) 1/240 0/38 WIBR-iPS-
SNCAA53T-Corr
1,2,3,4,5e
a Homologous and nonhomologous integration of donor vector (as analyzed in Figure S1).
b Insertion of A53T (G209A) mutation, as analyzed by Southern blot after TSP45I digest, genomic PCR mutation analysis, and sequencing.
c Loss-of-A53T (G209A) mutation, as analyzed by Southern blot after TSP45I digest, genomic PCR mutation analysis, and sequencing.
d 1A, 1B, and 1C represent different subclones of WIBR3-SNCAA53T/WT-1 after Cre-mediated excision of selection cassette.
e 1, 2, 3, 4, and 5 represent different subclones of WIBR-IPS-SNCAA53T-Corr after Cre-mediated excision of the reprogramming transgenes.
f 0/12 off-target modifications in lines WIBR3-SNCAA53T/WT-2 and WIBR3-SNCAA53T/WT-3.
g PCR mutation analysis-based screening strategy for E46K (G188A) mutation is not sensitive for modifications at the site of ZFN-induced DSB
(base 209).second allele resulting in a A53T mutated cell line on a genetic
BGO1 background (BGO1-SNCAA53T/WT). The targeted cell line
maintained a pluripotent state, as indicated by the uniform
expression of pluripotency-specific markers (Figure 2E) and
the ability to form teratomas (Figure 2F) and differentiate into
dopaminergic neurons in vitro (Figure 2G). The stable integration
of the ZFNs and GFP expression plasmids was excluded by
Southern blot analysis (Figure S3).
Insertion of the PD-Causing E46K (G188A) Point
Mutation into a-Synuclein in hESCs Using Single-
Stranded Oligodeoxynucleotides
Recent studies suggest that short single-stranded oligodeoxynu-
cleotides (ssODNs) instead of double-stranded donor plasmids
can be used as an alternative DSB repair template for ZFN-driven
genomeediting (Chenetal., 2011;Radeckeetal., 2006,2010).As it
has been shown that point mutations can be transferred distant
from the ZFN-induced DSB (Elliott et al., 1998; Goldberg et al.,
2010), we wanted to test the possibility of introducing a second
PD-causing mutation (E46K/G188A) into exon 3 of a-synuclein
(Zarranz et al., 2004) and therefore designed a 114 bp ssODN322 Cell 146, 318–331, July 22, 2011 ª2011 Elsevier Inc.carrying the disease-relevant G188A base pair change, located
21 bases upstream of the A53T (G209A) mutation (Figure 3A).
The hESC lines BGO1 and WIBR3 were electroporated with
ZFNs and an eGFP-expressing plasmid together with the ssODNs
instead of a double-stranded donor vector (Figure 3A). Individual
single-cell-derived clones from FACS-sorted eGFP-expressing
cells were screened by PCR followed by the mutation-specific
StyI restriction digest. Four out of 480 WIBR3 clones and one out
of 240 BGO1 clones showed the E46K (G188A) allele-specific
loss of the StyI restriction site as verified by PCR genotyping (Zar-
ranz et al., 2004) and Southern blot analysis (Figures 3B and 3C),
indicative of the accurate genetic alteration of the endogenous
a-synuclein genomic locus. Further analysis by sequencing
of the genomic locus confirmed the correct insertion of the E46K
(G188A) mutation without any additional alteration of the wild-
type or mutated allele adjacent to the ZFN cleavage site (Figures
3D and 3E). The targeted cell lines maintained a pluripotent state,
as indicated by the uniform expression of pluripotency-specific
marker proteins (Figures 3F and 3G). The efficiency of correctly
genomeeditedclonesusingssODNsas templatewascomparable
to that of using double-stranded donor plasmids (Table 1).
Genetic Repair of the A53T (G209A) a-Synuclein
Mutation in PD Patient-Derived hiPSCs
Fibroblasts obtained from a patient carrying the A53T (G209A)
a-synuclein mutation were reprogrammed using previously
described doxycycline-inducible and Cre-recombinase-excis-
able lentiviral vectors (Hockemeyer et al., 2008; Soldner et al.,
2009). The resulting hiPSCs before (WIBR-iPS-SNCAA53T(2lox))
(Figure 4) and after Cre-mediated excision of the reprogramming
factors (WIBR-iPS-SNCAA53T(1lox)) (Figure S2) displayed all basic
properties of pluripotent cells, as indicated by the uniform
expression of the pluripotency marker proteins (Figure 4A and
Figure S2B), the ability to form teratomas (Figure S2C), and a
normal karyotype (Figure 4B). Sequencing of the genomic
a-synuclein locus confirmed the A53T (G209A) mutation in the
patient-derived hiPSCs (Figure 4D). Furthermore, the cells
were shown to differentiate into TH-expressing dopaminergic
neurons (Figure 4E).
In order to genetically repair the A53T (G209) mutation in
the PD patient-derived hiPSCs, we employed a selection-free
targeting strategy, as described above for hESCs, with the
only difference of using a wild-type sequence-containing donor
vector (Figure 2A). Six out of 240 WIBR-iPS-SNCAA53T clones
demonstrated the loss of the A53T-specific Tsp45I restriction
site by Southern blot screening, which is either the result of
a ZFN-induced DSB followed by nonhomologous error-prone
end-joining or HDR-based correction of the allele (Figure 5A).
Further analysis by PCR genotyping (Figure 5B) and sequencing
of the genomic locus (Figure 5C) confirmed one correctly re-
paired patient-derived hiPSC line (WIBR-iPS-SNCAA53T-Corr;
Table 1) with the expected single base pair change of nucleotide
209 of a-synuclein. Finally, to prevent uncontrollable effects from
residual expression of the reprogramming transgenes (Soldner
et al., 2009), we excised the reprogramming vectors from the
corrected patient-derived hiPSCs (Figure S2D), which subse-
quently displayed a normal karyotype (Figure 5E), maintained a
pluripotent state as indicated by the uniform expression of the
pluripotency markers (Figure 5F), and displayed the ability to
form teratomas (Figure 5G). Stable integration of ZFNs, Cre-re-
combinase, and GFP expression plasmids was excluded by
Southern blot analysis (Figure S3). The genetic repair of the
A53T mutation in the patient-derived hiPSCs did not compro-
mise the ability to differentiate into TH-expressing dopaminergic
neurons (Figure 5H). To further validate accurate editing of the
a-synuclein locus in the repaired patient-derived hiPSC line
(WIBR-iPS-SNCAA53T-Corr), we performed mutation analysis RT-
PCR of a-synuclein after neuronal differentiation, confirming the
loss of expression of the mutated A53T (G209A) transcript
(Figure 5D).
Genome-wide Analysis of Engineered ESCs and iPSCs
A potential limitation of ZFN-mediated genome editing is the
induction of DNA strand breaks at sequences other than the in-
tended target site. To examine off-targetmodifications in the edi-
ted cell lines, we initially determined the DNA binding specificity
for each ZFN employed in this study by SELEX analysis, as
described previously (Hockemeyer et al., 2009; Perez et al.,
2008) (Table S3). This allows for the identification of the most
probable off-target cleavage sites genome-wide (Table S4). ASurveyor endonuclease (Cel-1) assay was subsequently per-
formed to reveal any potential nonhomologous end-joining
(NHEJ)-mediated indels for a large panel of putative off-target
sites in several of our edited cell lines (Table 1 and Figure S4).
Although this analysis has revealed rare bona fide off-target
modification by ZFNs in other studies (Hockemeyer et al.,
2009; Perez et al., 2008), we saw no evidence of off-target
genome disruption at any of the examined loci (Table1 and
Figure S4).
It is well established that prolonged culture of hESCs can lead
to adaption such as increased growth rate, reduced apoptosis,
and the acquisition of chromosomal abnormalities such as
copy number variations (CNVs) (Laurent et al., 2011; Na¨rva¨
et al., 2010).More recently, it has been proposed that the reprog-
ramming process itself compromises genomic integrity and
leads to the accumulating of CNVs and somatic mutations
(Gore et al., 2011; Hussein et al., 2011). Although all of our tested
cell lines showed a normal karyotype after genome editing as
determined by conventional karyotyping, the low resolution of
this technology excludes the detection of smaller CNVs, which
are considered a major source for human genome variability
and particularly important in the context of genome editing.
Such genetic modifications involve the induction of DNA
double-strand breaks and clonal events, which are thought to
increase the chance for additional genomic alterations. We
therefore performed high-resolution genome-wide CNV analysis
using an Affymetrix SNP 6.0 array, as described previously (Hus-
sein et al., 2011; Na¨rva¨ et al., 2010), on three pairs of isogenic
parental and genetically modified cell lines. We identified, on
average, 77 CNVs with an average size of 158 kb per cell line
(Table S5). For human ES cell lines, this is slightly higher than
described previously and may be due to technical variability
such as low sample or higher passage number of the cell lines
used in this study (between passage P25 and P60 for hESCs
andP22 andP40 for hiPSCs). Sixty-three percent of the identified
CNVs (number and total genomic area) overlapped between
isogenic pairs using pairwise comparison before and after
ZFNs-mediated genome modification (Figures S5A–S5E). In
contrast, we observed only 35% overlap of CNVs between
genetically unrelated samples (Figures S5A–S5E). This degree
of overlap is comparable to previously published hESC data
comparing identical cell lines at different passage numbers
(Figures S5D and S5E) (Na¨rva¨ et al., 2010). Furthermore,
comparing average number and total genome area of CNVs
before and after ZFN-mediated gene targeting did not reveal
any additional change other than that observed during regular
hESCs in culture (Figure S5F). Consistent with previous reports
(Na¨rva¨ et al., 2010), our analysis confirms that hESCs and hiPSCs
contain a higher number ofCNVs than the normal humangenome
independent of the genome editing procedure—probably
acquired during hESC derivation, the reprogramming process,
and prolonged cell culture. Moreover, we conclude that the
Cre-recombinase-mediated excision of the reprogramming
factors and ZFN-mediated genome editing did not substantially
increase the level of genomic alterations. To further validate
that the genome editing approach did not induce major genetic
or epigenetic alterations that would result in aberrant gene
expression profiles, we performed whole-genome expressionCell 146, 318–331, July 22, 2011 ª2011 Elsevier Inc. 323
Figure 2. ZFN-Mediated Insertion of the A53T a-Synuclein Mutation in hESC Line BGO1 without Drug Selection
(A) Schematic overview depicting the genomic a-synuclein (SNCA) locus and the targeting strategy showing exons (blue boxes), restriction sites, and location of
internal Southern blot probe (red bars). Enlarged sequence indicates ZFNs induced cut site at base 209 in exon 3 of a-synuclein (red base pair). Shown below is
a schematic of donor plasmid design and targeted genomic locus for either insertion (Donor-A53T) or correction (wild-type Donor) of A53T (G209A) a-synuclein
mutation. Donor plasmids contain 1 kb homology to the targeting site.
(B) Southern blot screening (30 internal probe) of BGO1 cells for targeted insertion of A53T (G209A) mutation (Donor-A53T). Genomic DNA was digested using an
A53T (G209A)-allele-specific Tsp45I restriction digest (A53T mutation creates additional Tsp45I restriction site). Expected fragment sizes: wild-type allele,
2.96 kb; A53T allele, 1.55 kb. 30 internal Southern blot probe excludes additional nonhomologous integration of the donor vector. Red asterisk indicates clonewith
additional Tsp45I restriction site indicative of insertion of A53T mutation.
(C) PCR mutation analysis of a-synuclein locus (± Tsp45I restriction digest) in patient-derived hiPSCs (WIBR-iPS-SNCAA53T) and targeted hESCs (BGO1-
SNCAA53T/WT represents clone marked by red asterisk in B). Fragment sizes (+ Tsp45I): wild-type allele, 219 bp; A53T allele, 131/88 bp.
(D) Sequencing of genomic a-synuclein locus in targeted hESC clone BGO1-SNCAA53T/WT displaying either wild-type allele (G209 in 7 out of 12 sequences) or
targeted mutant A53T allele (A209 in 5 out of 12 sequences).
(E) Immunofluorescence staining of BGO1-SNCAA53T/WT for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.
(F) Hematoxylin and eosin staining of teratoma sections generated from BGO1-SNCAA53T/WT cells.
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Figure 3. ZFN-Mediated Insertion of the E46K a-Synuclein Mutation in hESCs Using ssODNs
(A) Schematic overview depicting the genomic a-synuclein (SNCA) locus and the targeting strategy showing exon 3 (blue boxe), restriction sites, and location of
Southern blot probe (red bar). Enlarged sequence indicates ZFNs induced cut site at base 209 in exon 3 of a-synuclein and the site of the E46K (G188A) mutation
(red base pair). Shown below is a schematic of the 114 bp ssODN and the targeted genomic locus after insertion of E46K (G188A) a-synuclein mutation.
(B) PCR mutation analysis of a-synuclein locus (± StyI restriction digest) in hESC lines WIBR3 and BGO1 and targeted E46K hESC lines (WIBR3-SNCAE46K and
BGO1-SNCAE46K). Fragment sizes (+ StyI): wild-type allele, 153/66 bp; E46K mutated allele, 219 bp.
(C) Southern blot analysis (30 probe) of WIBR3 and BGO1 and targeted E46K hESC lines (WIBR3-SNCAE46K and BGO1-SNCAE46K) for targeted insertion of E46K
(G188A) mutation. Genomic DNA was digested using an E46K (G188A) allele-specific StyI restriction digest (E46K mutation disrupts wild-type allele specific StyI
restriction site). Expected fragment sizes: wild-type allele, 0.46 kb; E46K mutated allele, 2.96 kb.
(D) Sequencing of genomic a-synuclein locus in targeted hESC clone WIBR3-SNCAE46K displaying either wild-type allele (G188 in 10 out of 16 sequences) or
targeted mutant E46K allele (A188 in 6 out of 16 sequences).
(E) Sequencing of genomic a-synuclein locus in targeted hESC clone BGO1-SNCAE46K displaying either wild-type allele (G188 in 7 out of 16 sequences) or
targeted mutant E46K allele (A188 in 9 out of 16 sequences).
(F) Immunofluorescence staining of WIBR3-SNCAE46K for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.
(G) Immunofluorescence staining of BGO1-SNCAE46K for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.analysis of undifferentiated pairs of parental and genetically
modified cell lines. Despite very similar gene expression of all
pluripotent cell lines, hierarchical cluster analysis showed that
the influence of genetic background on gene expression is(G) Immunofluorescence staining of neuronal cultures derived from BGO1-SN
class III b-tubulin (TUJ1; green) and the dopaminergic neuron-specific marker tymore significant than the genome editing because gene expres-
sion patterns of pairs of parental and genome-edited cell lines are
more closely correlated than genetically independent cell lines
(Figure S5G).CAA53T/WT cells 10 days after induction of differentiation for neuron-specific
rosine hydroxylase (TH; red).
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Figure 4. Derivation of Disease-Specific
hiPSCs from PD Patient with A53T (G209A)
a-Synuclein Mutation
(A) Immunofluorescence staining of PD patient-
derived hiPSC line WIBR-iPS-SNCAA53T(2lox)-5 for
the pluripotency markers OCT4, NANOG, SOX2,
Tra-1-60, Tra-1-81, and SSEA4.
(B) Cytogenetic analysis of patient-derived hiPSC
line WIBR-iPS-SNCAA53T(2lox)-5 showing a normal
karyotype.
(C) Southern blot analysis of WIBR-iPS-
SNCAA53T(2lox) clones.GenomicDNAwasdigested
with XbaI and probed for proviral integrations
with 32P-labeled DNA probes against hOCT4,
hKLF4, hSOX2, and M2rtTA. Southern blot anal-
ysis confirms independent clones based on indi-
vidual proviral integration patterns.
(D) Sequencing of genomic a-synuclein locus
in PD patient-derived hiPSC line WIBR-iPS-
SNCAA53T(2lox)-5 showing both wild-type allele
(G209 in 7 out of 19 sequences) and mutant A53T
allele (A209 in 12 out of 19 sequences).
(E) Immunofluorescence staining of neuronal
cultures derived from hiPSC line WIBR-iPS-
SNCAA53T(2lox)-5 10 days after induction of differ-
entiation for neuron-specific class III b-tubulin
(TUJ1; green) and the dopaminergic neuron-
specific marker tyrosine hydroxylase (TH; red).DISCUSSION
Although transgenic animal models of disease and studying
human cultured cells in a Petri dish are core technologies driving326 Cell 146, 318–331, July 22, 2011 ª2011 Elsevier Inc.basic biomedical research, there are
many instances in which these ap-
proaches only partially recapitulate the
molecular and cellular changes observed
in the patient. The ability to generate an
unlimited supply of patient-derived,
disease-relevant cell types using hiPSC
technology has the potential to transform
biomedical research of human disease.
However, numerous challenges on the
path to well-defined experimental
in vitro systems must be resolved before
realizing the full promise of this tech-
nology. One of the crucial limitations
has been the inability to perform experi-
ments under genetically defined condi-
tions. Here, we present an elegant
solution to this problem by combining
the advantages of ZFN-mediated gene
editing such as the ability to engineer
ZFNs to target any locus in the genome
(Urnov et al., 2010) and easy donor
design, requiring only very short targeting
homologies, with hESC and hiPSC tech-
nology. The recent demonstration of
efficient gene editing in human pluripo-tent cell lines using transcription activator-like effector (TALE)
nucleases as an alternative strategy to induce site-specific
genomic DSBs will further expand the versatility of this approach
(Hockemeyer et al., 2011).
Table 2 compares the strengths and the weaknesses of the
four strategies described in this study. Although a gene-targeting
vector using positive-negative selection represents the most
efficient genome editing strategy, this approach requires the
deletion of the selection cassette and therefore necessitates
a second single-cell cloning step, adding time to generate
the final targeted cell line. Another unavoidable consequence
of the selection-based strategy is that it leaves a genetic
footprint, such as a loxP site, close to the targeted genetic
alteration. In contrast, the selection-free strategy, though less
efficient, leaves no genetic footprint and involves only one cell
cloning step and thus shortens the time required to generate
the targeted cell line. The simplicity of synthesizing ssODN-
based donors combined with the ability to transfer genomic
alterations adjacent to the ZFN induced DSB greatly increases
the versatility and applicability of the no-selection-based
approach and may represent the most advantageous option
for genome editing.
Here, we generated a panel of isogenic control and disease
cell lines on several defined genetic backgrounds by either
engineering the PD-related A53T or E46K mutation into hESCs
or, inversely, repairing the mutation in PD-patient-derived
hiPSCs by exclusively changing a single base pair without the
need to alter the genome in any other way. Considering
the broad influence of genetic background and the profound
biological differences between individual hESCs and hiPSCs,
such as the propensity to differentiate toward specific cell
lineages (Bock et al., 2011; Boulting et al., 2011), this experi-
mental system may overcome some of the shortcomings of
conventional hiPSC approaches in identifying disease-related
phenotypes. Robust disease-relevant in vitro phenotypes are
fundamentally important to identify new drug targets or allow
large-scale screening of genetic and small-molecule disease
modifiers. The availability of genetically defined pairs of disease
and control cell lines becomes even more significant in the
context of unbiased genome-wide analysis in order to distin-
guish between genetic background noise and disease relevant
effects, considering that the expression of 5% of genes is
thought to be linked to genetic variation (Montgomery et al.,
2010; Pickrell et al., 2010).
Though biomedical research is likely to benefit substantially
from in vitro disease modeling, the ultimate promise of iPSC
technology, albeit at a very early stage of development, is the
concept of cell replacement therapy in degenerative diseases
using autologous cells (Daley and Scadden, 2008). Proof-of-
principle experiments in the mouse (Hanna et al., 2007) have
established the feasibility of treating monogenic diseases using
the combined approach of derivation of disease-specific iPSCs
followed by in vitro repair of the underlying genetic alteration
and subsequent transplantation of corrected iPSC-derived cells.
Similar approaches with human cells are currently hindered by
the problem of efficient gene targeting required for repair of
disease-causing genomic alterations (Daley and Scadden,
2008). The methods described here for genetically correcting
a disease-causing point mutation in patient-derived hiPSCs
should be widely applicable and important both for elucidating
disease mechanism and for moving toward hiPSC-based cell
replacement therapies.EXPERIMENTAL PROCEDURES
HESC and hiPSC Derivation and Culture
HESC lines BG01 (NIH code: BG01; BresaGen, Inc., Athens, GA) and WIBR3
(Whitehead Institute Center for Human Stem Cell Research, Cambridge, MA)
(Lengner et al., 2010) and hiPSCs were derived and maintained as described
previously (Soldner et al., 2009) and in detail in the Extended Experimental
Procedures. The patient biopsied harbors the A53T a-synuclein mutation
and has been described previously (Golbe et al., 1996). All protocols were
approved by the relevant Institutional Review Boards (Boston University
Medical Campus; Massachusetts Institute of Technology) and Embryonic
Stem Cell Research Oversight Committees (Whitehead Institute), and written
informed consent was obtained before biopsy. All pluripotent cell lines have
been characterized by conventional methods, which are described in detail
in the Extended Experimental Procedures.
ZFN Design and ZFN Expression Plasmids
ZFNs against the human a-synuclein locus were designed using an archive of
prevalidated two-finger modules, as described (Doyon et al., 2008; Miller et al.,
2007; Perez et al., 2008; Urnov et al., 2005). Complete sequences of target
sites of the zinc finger proteins are provided in Table S1 and Table S2. All
ZFNs were linked to wild-type FokI, except pair SNCA-L1/R3, which was
linked to an obligate heterodimer form of the Fok1 endonuclease (ELD-KKR)
(Doyon et al., 2011;Miller et al., 2007; Perez et al., 2008). The ZFNswere tested
by transient transfection into K562 cells to test for disruption of the wild-type
a-synuclein allele. Disruption efficiency at the target locus was determined
by Surveyor (Cel-1) endonuclease-based measurement of nonhomologous
end-joining, as described (Miller et al., 2007; Perez et al., 2008) (primers
used in Cel-1 analysis: SNCA-Cel1-FW, 50-AAACTAGCTAATCAGCAATT
TAAGGC-3; SNCA-Cel1-RW, 50-AGCCCTCATTATTCTTGGCA-3). Analysis
of off-target cleavage by ZFNs, which results in NHEJ-mediated indels, was
performed essentially as described before (Doyon et al., 2008; Hockemeyer
et al., 2009; Perez et al., 2008) and is described in detail in the Extended
Experimental Procedures.
ZFN-Mediated Genome Editing of hESCs and hiPSCs
HESCs and hiPSCs were cultured in Rho-associated protein kinase (ROCK)
inhibitor (Calbiochem; Y-27632) 24 hr prior to electroporation. Cells were har-
vested using 0.05% trypsin/EDTA solution (Invitrogen) and were resuspended
in phosphate buffered saline (PBS). For drug selection-based gene editing, 13
107 cells were electroporated with 35 mg of donor plasmids (designed and
assembled by F.S.) and 7.5 mg of each ZFN-encoding plasmid (Gene Pulser
Xcell System, Bio-Rad: 250 V, 500 mF, 0.4 cm cuvettes). Cells were subse-
quently plated on DR4 MEF feeder layers in hESC medium supplemented
with ROCK inhibitor for the first 24 hr. Ganciclovir (1 3 106 M) and/or puro-
mycin selection (0.5 mg/ml) was started 72 hr after electroporation. For drug
selection-free gene editing, 1 3 107 cells were electroporated with 30 mg of
donor plasmids (designed and assembled by F.S.), 7.5 mg of each ZFN-encod-
ing plasmid, and 10 mg of pEGFP-N1 (Clontech). For gene editing using
ssODNs, 13 107 cells were electroporated with 7.5 mg of each ZFN-encoding
plasmid and 15 mg of pEGFP-N1 (Clontech) together with 30 mg of ssODNs
(50-GACTTATGTCTTGAATTTGTTTTTGTAGGCTCCAAAACCAAGAAGGGAG
TGGTGCATGGTGTGGCAACAGGTAAGCTCCATTGTGCTTATATCCAAAGAT
GATATTTAAAGTAT-30; Integrated DNA Technologies, Iowa). Cells were
maintained on MEF feeder layers for 72 hr in the presence of ROCK Inhibitor
followed by FACS sorting (FACS-Aria; BD-Biosciences) of a single-cell
suspension for eGFP-expressing cells and were subsequently plated at
a low density in hESC medium supplemented with ROCK inhibitor for the first
24 hr. Individual colonies were picked and expanded 10–14 days after
electroporation.
ACCESSION NUMBERS
ExpressionMicroarray data and SNP 6.0 CNV array data have been submitted
to the Gene Expression Omnibus (GEO) and are available under accession
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Figure 5. ZFN-Mediated Correction of A53T (G209A) Mutation in PD Patient-Derived hiPSCs
(A) Southern blot screening (30 internal probe) of patient-derived hiPSCs (WIBR-iPS-SNCAA53T) for correction of A53T (G209A) mutation (wild-type Donor).
Genomic DNA was digested using an A53T (G209A) allele-specific Tsp45I restriction digest (A53T mutation creates additional Tsp45I restriction site). 30 internal
Southern blot probe excludes additional nonhomologous integration of the donor vector. Fragment sizes: wild-type allele, 2.96 kb; A53T allele, 1.55 kb. Red
asterisk indicates clone with loss of Tsp45I restriction site, indicative of loss of A53T mutation.
(B) PCRmutation analysis of genomic a-synuclein locus (± Tsp45I restriction digest) in hESCs (WIBR3) and patient-derived hiPSCs before (WIBR-iPS-SNCAA53T)
and after correction (WIBR-iPS-SNCAA53T-Corr-1 and -5, representing two subclones from clonemarked by red asterisk in A). Fragment sizes (+Tsp45I): wild-type
allele, 219 bp; A53T mutant allele, 131/88 bp.
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Table 2. Comparison of the Four Different Targeting Strategies
Strategy Donor Targeting Steps Time Requireda Efficiencyb Strengths Drawbacks
Selection
based
positive
selection
positive-negative
selection
2
2
8–16 weeks
8–16 weeks
+
++
high efficiency; use
of multiple selection
markers allows for
targeting of both alleles
same as above
complex vector design;
two clonal steps;
genetic alteration
(remaining loxP site)
same as above
No selection vector-based
donor
ssODN
1
1
4–8 weeks
4–8 weeks
+
+
one clonal step; no
additional genetic
alterations
in addition, easy
donor design
complex vector design
a Time between electroporation and identification of modified cell line.
b +  1%; ++  10% (efficiencies may vary for different genes).SUPPLEMENTAL INFORMATION
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